Forecast
The analysts' average price target is €1.49 (-46.79%). The median is €1.49 (-46.79%).
| Buy |
3 |
| Hold |
3 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
In the last quarter, Aadi Bioscience had revenue of €0 and net profit of -€18.72m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -18.72m | 23.82% |
| EBITDA | -20.26m | 33.95% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €86.48m |
Number of shares | 46.29m |
52-week high/low | €3.47 - €1.10 |
| Dividends | No |
Beta | 0.34 |
P/E ratio | -2.82 |
PEG ratio | 0.00 |
P/B ratio | 1.77 |
P/S ratio | 0.00 |
Company profile
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Name | Aadi Bioscience |
| CEO | David J. Lennon |
| Headquarters | Pacific Palisades,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 16/02/2018 |
| Employees | 53 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | AADI |
Frankfurt | 3350.F |
Düsseldorf | 3350.DU |
München | 3350.MU |
NASDAQ | WHWK |